case studies
Real Clients. Real Results.
Liquid Biopsy Assay
Developed a launch strategy for a liquid biopsy assay, including a map of the current diagnostic paradigm, payer evidentiary thresholds, and barriers to use. Identified viable strategies to drive adoption, and developed a tactical market access action plan for the client to execute for a successful launch.
Novel International Molecular Diagnostic System
For a novel molecular diagnostic system in the US and seven EU countries, gained internal alignment on pricing to determine current estimated costs, expert views of the novel system, value of savings associated with system adoption, acceptable costs, and impact of future changes in regulation and reimbursement.
Minimal Residual Disease Test
Provided a roadmap for a molecular diagnostics company developing a new technology to detect minimal residual disease to secure Current Procedural Terminology (CPT) coding and positive Medicare coverage and reimbursement in the US.
Prostate Cancer Prognostic Assay
Created a comprehensive payer launch engagement strategy for a prostate cancer prognostic assay, including timelines for engagement, strategic communication approaches, and a targeted group of payers known to be early adopters.
Go-to-Market Strategy Development and Execution for Progyny
To accelerate market adoption most efficiently and cost-effectively, ADVI worked with senior leadership at Progyny to secure an anchor partnership agreement with one of the major benefits consulting firms.
Evaluation and Strategic Planning for Combination Pricing
The ADVI team drew from its extensive industry experience with Part B MAC engagement to optimally prepare the client for MAC/CAC engagement; analyzed comparator products to gauge likely MAC treatment; and engaged former MAC Contractor Medical Directors for insights and coverage assumptions testing.
Strategic Planning for Part B Launch
The ADVI team drew from its extensive industry experience with Part B MAC engagement to optimally prepare the client for MAC/CAC engagement; analyzed comparator products to gauge likely MAC treatment; and engaged former MAC Contractor Medical Directors for insights and coverage assumptions testing.
Value/Price Message Development for Executive Team
Prepared an executive team for drug pricing and value debate, and assisted in training field-based personnel on customer reimbursement/pricing/value questions.
Evaluation of Indication-Based Pricing for Oncology Biologic
Evaluated potential strategies to implement Indication Based Pricing (IBP) and understand the impact to ASP and other reimbursement/payment metrics surrounding an oncology biologic.
White Paper Development on Policy Landscape for Bio/Pharma Industry
ADVI conducted significant secondary and primary research with payors and oncologists, as well as Washington policy thought leaders, to identify key trends and potential future approaches to oncology payment reform.
Secure Channel Relationships
ADVI secured channel relationships with the two largest benefits consulting companies to accelerate market adoption among the largest self insured employers.
Medicare Coverage
For a client that required targeted quality metrics to foster appropriate provider usage of medical devices, ADVI created and assessed a measurement landscape to identify gaps in measurement and opportunities for development of measures related to product line.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.